Repligen Past Earnings Performance
Past criteria checks 2/6
Repligen has been growing earnings at an average annual rate of 34.3%, while the Life Sciences industry saw earnings growing at 22.2% annually. Revenues have been growing at an average rate of 26.7% per year. Repligen's return on equity is 2.1%, and it has net margins of 6.5%.
Key information
34.3%
Earnings growth rate
32.1%
EPS growth rate
Life Sciences Industry Growth | 19.5% |
Revenue growth rate | 26.7% |
Return on equity | 2.1% |
Net Margin | 6.5% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Repligen makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 639 | 42 | 216 | 43 |
30 Sep 23 | 670 | 116 | 210 | 44 |
30 Jun 23 | 729 | 138 | 209 | 43 |
31 Mar 23 | 778 | 168 | 215 | 44 |
31 Dec 22 | 802 | 186 | 216 | 44 |
30 Sep 22 | 801 | 166 | 210 | 42 |
30 Jun 22 | 779 | 159 | 204 | 41 |
31 Mar 22 | 734 | 146 | 194 | 39 |
31 Dec 21 | 671 | 128 | 184 | 34 |
30 Sep 21 | 593 | 119 | 164 | 32 |
30 Jun 21 | 509 | 100 | 145 | 27 |
31 Mar 21 | 433 | 80 | 127 | 23 |
31 Dec 20 | 366 | 60 | 116 | 20 |
30 Sep 20 | 327 | 44 | 112 | 19 |
30 Jun 20 | 302 | 31 | 107 | 20 |
31 Mar 20 | 286 | 23 | 100 | 21 |
31 Dec 19 | 270 | 21 | 96 | 19 |
30 Sep 19 | 253 | 23 | 81 | 17 |
30 Jun 19 | 233 | 27 | 72 | 16 |
31 Mar 19 | 210 | 21 | 69 | 16 |
31 Dec 18 | 194 | 17 | 66 | 16 |
30 Sep 18 | 184 | 23 | 64 | 16 |
30 Jun 18 | 171 | 23 | 64 | 14 |
31 Mar 18 | 155 | 29 | 58 | 10 |
31 Dec 17 | 141 | 28 | 52 | 9 |
30 Sep 17 | 125 | 21 | 43 | 8 |
30 Jun 17 | 113 | 18 | 34 | 8 |
31 Mar 17 | 110 | 13 | 31 | 8 |
31 Dec 16 | 105 | 12 | 31 | 7 |
30 Sep 16 | 100 | 7 | 27 | 7 |
30 Jun 16 | 96 | 8 | 28 | 6 |
31 Mar 16 | 88 | 8 | 25 | 6 |
31 Dec 15 | 84 | 9 | 25 | 6 |
30 Sep 15 | 78 | 9 | 23 | 6 |
30 Jun 15 | 74 | 8 | 21 | 6 |
31 Mar 15 | 68 | 7 | 19 | 6 |
31 Dec 14 | 64 | 8 | 16 | 6 |
30 Sep 14 | 63 | 12 | 15 | 6 |
30 Jun 14 | 66 | 16 | 14 | 5 |
31 Mar 14 | 68 | 18 | 13 | 6 |
31 Dec 13 | 68 | 16 | 13 | 7 |
30 Sep 13 | 72 | 22 | 13 | 8 |
30 Jun 13 | 68 | 18 | 13 | 9 |
Quality Earnings: R2GE34 has high quality earnings.
Growing Profit Margin: R2GE34's current net profit margins (6.5%) are lower than last year (23.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: R2GE34's earnings have grown significantly by 34.3% per year over the past 5 years.
Accelerating Growth: R2GE34's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: R2GE34 had negative earnings growth (-77.6%) over the past year, making it difficult to compare to the Life Sciences industry average (-1.1%).
Return on Equity
High ROE: R2GE34's Return on Equity (2.1%) is considered low.